Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bandwidth Inc (BAND) vs BioNTech SE - ADR (BNTX) Price & Performance

Bandwidth IncTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Bandwidth Inc vs BioNTech SE - ADR — how do they compare? Bandwidth Inc trades at $77.48 (market cap $2.36B), while BioNTech SE - ADR trades at $89.89 (market cap $22.86B). The key difference: BioNTech SE - ADR is far larger — about 9.7× Bandwidth Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BANDBNTX
Market Cap
$2.36B$22.86B
Sector
TechnologyHealth
52-Week High
$78.44$119.34
52-Week Low
$12.82$83.89
Enterprise Value
$2.74B$6.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bandwidth Inc

Bandwidth (BAND) trades at $73.81, down 2.21% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations of $0.32, while revenue reached $753.82 million in 2025. Analyst sentiment is positive with 12 buy ratings and a consensus price target of $71.67. Recent news highlights AI-driven growth in cloud communications and a $275 million convertible notes offering to fuel expansion.

The outlook for BAND is cautiously optimistic, driven by AI infrastructure demand and cloud communications growth. Key risks include negative profit margins and high valuation multiples. Investment opportunity lies in execution of AI initiatives, but investors should monitor earnings sustainability and competitive pressures in the technology sector.

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bandwidth Inc

Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.

Read more on BAND

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX